US biotech Novavax has begun a phase 1 study of its coronavirus vaccine, as the number in clinical development reached double figures. The World Health Organization has been keeping tabs on ...

Although Pfizer's and Moderna’s COVID-19 vaccines have been stealing the spotlight for years, some people are actively ...

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by ...

The purpose of the OWS grant was to enable Novavax to ... and deliver 100 million doses of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate, as early as late 2020. Novavax undertook ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs says the company is at a pivot point.

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine ... employment with Novavax, effective as of November 11, 2024 (the "grant date").

India has bought 1.6 billion doses of Covid-19 vaccines ... of the Oxford University-AstraZeneca vaccine candidate, one billion from the American company Novavax and 100 million doses of the ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax ...